Biodesix (BDSX) Cost of Revenue (2019 - 2026)

Biodesix (BDSX) has reported Cost of Revenue for 8 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $4.2 million, up 13.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (up 76.54% YoY), and the FY2025 annual result was $7.6 million, changed 0.16% from the prior year.
• Cost of Revenue was $4.2 million for Q1 2026 at Biodesix, up from $2.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $4.2 million in Q1 2026 and troughed at -$3.7 million in Q4 2024.
• Average Cost of Revenue over 5 years is $3.0 million, with a median of $3.4 million recorded in 2023.
• Year-over-year, Cost of Revenue sank 208.39% in 2024 and jumped 153.62% in 2025.
• Over 5 years, Cost of Revenue stood at $3.3 million in 2022, then advanced by 2.06% to $3.4 million in 2023, then tumbled by 208.39% to -$3.7 million in 2024, then soared by 153.62% to $2.0 million in 2025, then jumped by 114.43% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $4.2 million in Q1 2026, $2.0 million in Q4 2025, and $4.1 million in Q3 2025.